Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288805 | 0.94 | NPC1 (0.52) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL3297167 | 0.94 | KDM4E (0.47) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL3289866 | 0.90 | PRKAA2 (0.46) | PRKAA2NPC1RAB9ASMOHTR2B | |
| SCHEMBL3291473 | 0.90 | KCNK3 (0.51) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL13329172 | 0.89 | NPC1 (0.47) | PRKAA2NPC1RAB9AKDM4EGAA | |
| SCHEMBL3288782 | 0.89 | RAB9A (0.46) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL3290021 | 0.89 | KDM4E (0.48) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL3290350 | 0.88 | KDM4E (0.50) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL3291818 | 0.88 | GAA (0.48) | PRKAA2NPC1RAB9ASMOPGR | |
| SCHEMBL4081256 | 0.88 | KDM4E (0.49) | PRKAA2NPC1RAB9ASMOPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | PRKAA2 2191/4885NPC1 448/4885RAB9A 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.